- GoldenBiotech Antroquinonol Granted Compassionate Use in Taiwan for Treating Covid-19 Patients
- Covid-19 Trial: GoldenBiotech New Drug Antroquinonol Passed 2nd DMC Review in the USA
- GoldenBiotech Presents Outstanding Results of Potential Treatment for Relapsed AML in ASCO 2021
- GoldenBiotech Completes Second Interim of Patients Enrollment for Covid-19 Phase 2 Clinical Trial
- Covid-19 Drug Duo Achievements: GoldenBiotech’s New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
- GoldenBiotech Signed First Licensing Agreement with BNC Korea for its New Drug Antroquinonol® (HOCENA®) to Treat Covid-19 in the Designated Territories
- Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia
- Coronavirus Covid-19 Clinical Trial Agreement Signed – Partnering with Ascension Via Christi in USA Advancing GoldenBiotech’s New Drug Antroquinonol
- GoldenBiotech Signed MOU with BNC Korea for Cooperation and Licensing of Covid-19 New Drug Antroquinonol in South Korea.
- BIO Asia Taiwan 2020 Exhibition Highlights-“GoldenBiotech Can Help!” Featuring Progress of Antroquinonol on COVID-19 Phase 2 Trial in USA
- The Associated Press- Anti-viral and Anti-Inflammatory Response: GoldenBiotech’s Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA
- Bloomberg- Anti-viral and Anti-Inflammatory Response: GoldenBiotech’s Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA
- Anti-viral and Anti-Inflammatory Response: GoldenBiotech’s Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA
- GoldenBiotech’s Antroquinonol Completed Phase 1 Trial and Started Phase 2 for Metastatic Pancreatic Cancer as First Line Treatment
- USA National Institutes of Health (NIH)- National Cancer Institute(NCI) Listed the term of drug name: Antroquinonol ( HOCENA)
- GoldenBiotech Antroquinonol Phase 2 NSCLC Clinical Study Presents Brilliant Results in ASCO Meeting.
- Golden Biotechnology Corp. Starts Phase 2 Trial for Efficacy of Antroquinonol in AML after Russian MOH Approval
- Golden Biotechnology Corp. was Granted the Patent for Treating Fatty Liver Diseases by the European Patent Office
- Golden Biotechnology Corp. Met Targets in Clinical Trial of Antroquinonol for Hypercholesterolemia and Hyperlipidemia
- Golden Biotechnology Corp. Receives US Patent Approval for Treating Neurodegenerative Diseases
- Golden Biotechnology Corp. Acquires Japanese Patent for Treating Arteriosclerosis Disease
- Golden Biotechnology Corp. Completed Registration in ClinicalTrials of NIH for its New Drug Clinical Trial in treatment of Pancreatic Cancer
- Golden Biotechnology Corp. Awarded USP GMP Audit Certificate and Meets GMP Requirement in ICH-GMP for API
- Golden Biotechnology works with Queensland QUT on Alzheimer’s cure
- FDA Grants a Clinical Trial of Antroquinonol in combination with standard Nab-paclitaxel plus Gemcitabine as First-Line Therapy for Pancreatic Cancer
- European Commission has granted Antroquinonol orphan medicinal product designation for treatment of pancreatic cancer.
- New Drug Hocena for treating of cancer and hyperlipidemia won National Innovation Award in Taiwan.
- Golden Biotechnology wins worldwide contest for potential treatment of Alzheimer’s Disease
- Golden Biotechnology Hocena Surpassed Expectations on NSCLC Phase II /Stage 1 Trial
- GoldenBiotech’s research shows Antroquinonol modulates the pathogenesis of Alzheimer’s disease.
- GoldenBiotech’s New Drug GHHCC was Granted Orphan Drug Designation for Hepatocellular Carcinoma by FDA
- Golden Biotechnology Antroquinonol Granted Orphan Drug Designation by USFDA for Treatment of Acute Myeloid Leukemia (AML)
- Golden Biotechnology Antroquinonol Granted Orphan Drug Designation by USFDA for Treatment of Pancreatic Cancer
- GoldenBiotech’s new cancer drug Hocena® has been awarded the “Research and Development Innovation Award” in Taipei Biotech Awards 2014.
- Lung cancer drug approved for phase two clinical trials